Dyne Therapeutics, Inc. (DYN) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Dyne Therapeutics, Inc.
Address
1560 Trapelo Road
Waltham, MA 02451
United States of America (the)
Phone
781 786 8230
Website
Sector
Healthcare
Industry
Biotechnology
Employees
289
First IPO Date
September 17, 2020
Key Executives
| Name | Title | Pay | Year Born |
| John G. Cox | Chief Executive Officer, President & Director | 1.14M | 1963 |
| Erick J. Lucera | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer and Treasurer | 726,892 | 1968 |
| Oxana Beskrovnaya | Chief Innovation Officer | 740,475 | 1961 |
| Douglas Kerr | Head of Research & Development and Chief Medical Officer | 748,065 | 1967 |
| Johanna Friedl-Naderer | Chief Commercial Officer | 842,754 | 1968 |
| Rajesh Manchanda | Chief Technical Officer | 0 | 1967 |
| Alessandro Martuscelli | Chief Legal Officer | 0 | N/A |
| James Bilotta | Chief Digital & Information Officer | 0 | N/A |
| Debra Feldman | Chief Regulatory Affairs Officer | 0 | 1971 |
| Lucia Celona | Chief Human Resource Officer | 0 | 1966 |
| Axel Wiest | Senior VP and Head of Portfolio Strategy & Operations | 0 | N/A |
Description
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
